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There is a high incidence of non-Hodgkin's lymphoma in
patients with impaired cell-mediated immunity, including
patients with congenital immunodeficiency and iatrogenically
immunosuppressed allogeneic transplant recipients. A signi-
ficantly increased incidence of lymphoma has also been dem-
onstrated in HIV infected patients and within this group the
prevalence is rising. This rise reflects not only the increasing
number of people infected with the HIV virus, but also their
improved survival as a consequence of advances in antiretro-
viral therapy and the more effective management of oppor-
tunistic infections. The HIV-associated lymphomas (HAL)
form two groups of different histology, prognosis and patho-
genesis; the Burkitt's lymphomas, and the diffuse large cell
and immunoblastic lymphomas. This review will focus on the
molecular biology of these lymphomas.
Burkitt's lymphoma
Approximately a third of HIV-associated lymphomas are
small non-cleaved cell Burkitt-like lymphomas (Ziegler et al.,
1984; Knowles et al., 1988; Lowenthal et al., 1988; Roith-
mann et al., 1991). Burkitt's lymphoma (BL) is not assoc-
iated with congenital or iatrogenic immunosuppression and
in HIV infected patients BL occurs at all stages of the disease
including patients with normal CD4 cell levels. The develop-
ment of BL does not therefore seem to be related to the
extent of immunodeficiency. Outside of the context of HIV
there are two forms of BL; endemic BL (eBL), and sporadic
BL which differ in both their clinical manifestations, and
their molecular pathology. Endemic BL occurs in children in
the malaria belt of central and eastern Africa who usually
present with jaw or orbital masses. Sporadic BL has no
geographic association and affects young adults most fre-
quently causing intra-abdominal lymphadenopathy.
Both forms of Burkitt's lymphoma are characterised by
chromosomal translocations involving the c-myc oncogene
on chromosome 8 and one of the immunoglobulin genes
(IgH on chromosome 14, IgLic on chromsome 2, or IgLA on
chromosome 22). Cytogenetically these translocations are
identical in endemic and sporadic BL. However, the precise
molecular location of the breakpoints on both chromosome 8
and 14 vary (Pellici et al., 1986). In endemic BL which is
consistenly associated with Epstein-Barr virus (EBV), breaks
occur up to 75 kB 5' (upstream) of the c-myc oncogene; in
sporadic BL most of the translocations occur around exon-1
of c-myc (Shiramizu et al., 1991). Although these latter
breakpoints alter the c-myc RNA transcript, the region
affected is untranslated and so the amino acid sequence of
the myc protein is unchanged. The overall consequence of
both rearrangements is increased expression of myc protein
rather than a qualitative change. Myc protein is a nuclear
DNA binding protein containing two structural domains, the
leucine zipper domain and the helix-loop-helix motif
previously identified in transcription factors. Myc protein
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forms a heterodimer with Max, another leucine zipper DNA
binding protein, and alters the expression of a large number
of cellular genes. All proliferating tissues express at least one
member of the myc family, usually c-myc. Deregulation of
myc expression in transfection experiments prevents inducible
cell differentiation (Coppola & Cole, 1986; Prochnownik &
Kukowska, 1986). The Ig/myc translocation which results in
constitutive expression of myc, may contribute to the patho-
genesis of BL by preventing the programmed exit of lympho-
cytes from the cycling compartment. C-myc gene re-
arrangements have been identified in HIV-associated BL and
most resemble sporadic BL at the molecular level (Subar et
al., 1988). The scattering of c-myc breakpoints means that
some c-myc gene rearrangements may be missed by Southern
blotting if only a limited number of restriction enzyme diges-
tions are undertaken.
The sites of breakpoints within the IgH gene on chromo-
some 14 vary between endemic and sporadic BL, and this
may reflect defects occurring at different stages of gene re-
arrangement during B-cell ontogony. Endemic BL is charac-
terised by breaks in the diversity (DH) or joining (JH) regions
of IgH which form a component of the antigen binding site
of antibodies by VH-DH-JH recombination. In contrast, the
switch region lying between JH and Cl, regions of IgH is the
commonest site of breaks in sporadic BL and these are
involved in isotypic class switching from IgM to IgG, IgA or
IgD, which occurs at a later point in B-cell differentiation.
These molecular variations are mirrored in the immuno-
phenotype of the lymphoma cells. Endemic BL cells are more
immature with cytoplasic la heavy chains resembling early
follicle centre cells whereas sporadic BL have cell surface IgG
and are similar to medullary pre-B lymphocytes. HIV-assoc-
iated BL are similar to sporadic BL in the location of breaks
in IgH and c-myc genes, and their more mature immuno-
phenotype (Subar et al., 1988).
The geographic association with malaria and the frequent
presence of EBV genome within tumour cells are found in
endemic BL, but not in either sporadic BL or HIV-associated
BL. Endemic malaria leads to hyperstimulation of the
humoural immune system and secondary suppression of cell
mediated immunity. HIV infection induces a vigorous
immune response with a 10-fold increase in polyclonal
immunoglobulin production. Polyclonal B cell activation by
HIV may be a direct mitogenic effect or may be antigen-
specific (Schnittman et al., 1986). Parasite induced T cell
immunosuppression and polyclonal B-cell activation are thus
features of both HIV and malaria infection and suggests that
HIV infection may be performing an analogous role to holo-
endemic malaria in the pathogenesis of BL. The predomin-
ance of sporadic BL in HIV infection rather than endemic
BL reflects the stage of B-cell ontotogony at which chromo-
some rearrangement errors take place. In general errors occur
during VHDHJH recombination in the presence of EBV (eBL)
but occur later during isotype class switching in the absence
of EBV (sBL).
A further potential mechanism in the pathogenesis of HIV
associated BL involves interleukin-6 secretion by HIV
infected macrophages. Interleukin-6 is a B cell stimulatory
factor which enhances the growth of EBV transformed lym-
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phoblastoid cell lines in vitro and may therefore have a role
in the development of BL. Other factors that have been
identified as possible agents in this process include mutations
of the tumour suppressor gene p53 (Giadano et al., 1991)
and secondary non-random chromosomal abnormalities of
band 13q34 (Berger et al., 1989).
Large cell and immunoblastic lymphomas
Diffuse large cell lymphoma (LCL) and immunoblastic lym-
phoma (IBL) make up two thirds of all HIV associated
lymphomas including all primary cerebral lymphomas
(Ziegler et al., 1984; Knowles et al., 1988; Lowenthal et al.,
1988; Roithman et al., 1991). Although classified as inter-
mediate grade in the working formulation LCL behaves as
an aggressive tumour in AIDS patients and is usually con-
sidered together with IBL as a single disease group. These
lymphomas occur most frequently in older patients with
advanced immunosuppression. In one large French study of
HAL, the mean CD4 cell counts at lymphoma presentation
were 80iLl-' (IBL), and 125pl-' (LCL) compared to 266 tlI
(BL) (Roithman et al., 1991).
Histologically similar lymphomas develop in both congeni-
tally and iatrogenically immunosuppressed patients (Hanto et
al., 1985), and in these latter the EBV genome has been
demonstrated in the majority of tumours by DNA in situ
hybridisation. The linear EBV genome contains multiple
tandem copies of a 500bp terminal repeat unit at either end
which is involved in circularisation to form covalantly closed
episomal DNA following viral infection of host cells.
Genomic terminus analysis maybe used to assess the clonality
of transplant associated lymphoproliferative disorders, and
has advantages over Ig gene rearrangement studies since the
latter are not completely stable clonal markers (Cleary et al.,
1988a). Biopsy specimens from different sites in individual
patients demonstrated different EBV genomic terminus fusion
configurations confirming the multiclonal origin of these lym-
phoproliferative disorders. However, a single clonal band was
detected in most biopsies suggesting that all tumour cells at
one site were infected with a single form of the EBV genome
and that B-cell proliferation probably occurred after EBV
infection (Cleary et al., 1988b). In addition, EBV has an
aetiological role in the development of several other diseases
in the immunocomprised patient. Primary EBV infection in
HIV infected children is thought to cause lymphocytic inters-
titial pneumonitis (Andiman et al., 1985) and replicative lysogenic cycle EBV is implicated in the development ofhairy
leukoplakia in HIV infected patients (Greenspan et al., 1985).
In contrast, transplantation associated lymphomas, EBV-
transformed lymphoblastoid cell lines and HAL all contain
latent EBV expressing a restricted number of viral genes
(EBNA1-6, LMP1-2 - Young et al., 1989; Thomas et al.,
1990). These findings suggest a possible pathogenetic role for
EBV in HIV-associated LCL and IBL.
Disruption of the EBV-host relationship allows activation
of the latent carrier state with serological evidence of viral
reactivation, oropharyngeal shedding of viral particles and
increased levels of circulating EBV-infected B lymphocytes.
In X-linked lymphoproliferative disease (Purtilo & Grierson,
1991) and allograft recipients, there is a decrease in cytotoxic
T-cell activity against EBV and these patients develop lym-
phomas containing EBV. A similar reduction of the cytotoxic T lymphocytes mediated suppression of EBV induced
antibody secretion in vitro, and increased circulating cells
containing EBV in vivo has been demonstrated in HIV
infected patients (Birx et al., 1986). This loss of cell mediated
control of EBV is progressive, and as CD4 levels fall there is
a concomitant rise in the incidence of IB and LCL lym- phomas.
EBV has been detected by DNA in situ hybridisation in
about 30-50% of these HIV associated LCL and IB lym- phomas although there appears to be regional variation with
higher rates reported from New York than San Francisco
(Cremer et al., 1990), which may relate to the low sensitivity
of this methodology. Viral DNA in cell lines transformed by
latent EBV infection is present in low copy numbers making
detection by DNA in situ hybridisation difficult and a similar
situation may occur in HIV associated lymphomas producing
false negative results. The detection of EBV in tumour cells is
hampered by the low sensitivity (e.g. DNA in situ hybridisa-
tion) or the lack of cellular specificity (e.g. Southern blotting
and polymerase chain reaction) of the methods used. Some of
these difficulties have been overcome by RNA in situ hybri-
disation for EBERs. EBERs are short non-protein coding
non-polyadenylated viral RNA transcripts expressed in abun-
dance in the nuclei of cells during latent EBV infection
(Arrand & Rymo, 1982). Their detection by in situ hybridisa-
tion binding to antisense probes has been used to demon-
strate latent EBV infection in all 21 cases of AIDS-related
primary CNS lymphoma studied (MacMahon et al., 1991).
This technique has yet to be applied to systemic HAL.
Although EBV induced lymphoproliferation appears to
account for the transplantation associated lymphomas and
some HAL, the absence of detectable EBV in many cases of
HAL suggests other factors may play a role. Amongst the
candidates is the HIV virus itself, although these lymphomas
do not contain HIV proviral DNA within tumour cells.
3-15% HIV infected patients develop an oligoclonal or
monoclonal paraprotein and this is frequently directed at
HIV antigens (e.g. gag/pol proteins) (Ng et al., 1989). Fur-
thermore, NG described a patient with HAL whose tumour
secreted a monoclonal paraprotein directed at the gp 160
antigen of HIV (Ng et al., 1990). It would appear that in this
instance HIV is playing a role in lymphomagenesis by anti-
gen specific B cell activation. Herndier has recently described
a high grade lymphoma in a patient with AIDS which
demonstrated both genotypc (T-cell receptor P-chain gene
rearrangement) and immunophenotypic (CD4+, CD5+
CD45RO+) features of T-cell lymphoma. The tumour exp-
ressed interleukin 2 receptor (IL-2R) and produced both IL-2
and IL-2R RNA transcripts analogous to HTLV-1 associated
adult T-cell leukaemia/lymphoma (ATLL) but without
detectable HTLV-1 or EBV. Southern blot analysis showed
monoclonally integrated HIV-1 in the tumour genome and
immunocytochemistry demonstrated HIV p24 antigen in
tumour cells. In this rare T-cell HAL HIV appears to be
implicated in lymphomagenesis althought the mechanism re-
mains uncertain. HIV integration may occur at or near cel-
lular oncogenes leading to deregulated expression and cell
transformation. Alternatively the HIV tat gene product may
stimulate IL-2 production, and the presence of IL-2R on
tumour cells may complete an autocrine loop stimulating
tumour proliferation (Herndier et al., 1992).
Transplantation-associated lymphomas and HAL both
express EBV latent cycle antigens and the tumours are
therefore susceptible to cell-mediated immunity. Following
transplantation T-cell function is suppressed to reduce graft
rejection, and a reduction in this immunosuppressive therapy
may lead to regression of transplantation-associated lym-
phomas (Starzl et al., 1984). This therapeutic option is not
available to AIDS patients, and the very poor outlook for
these HAL patients brings into question the value of any
treatments other than symptom palliation. In contrast HIV
infected patients with BL have a higher remission rate and
longer median survival, including a few documented sur-
vivors at 3 years (Roithmann et al., 1991). In view of this,
these patients may be suitable candidates for aggressive
chemotherapy regimes. The search for aetiological factors in
HIV-associated lymphomas continues and may shed light not
only on the increasingly prevalent immunodeficiency related
tumours, but also on lymphomagenesis in general.
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